author-photo

Shannon McGrath

Eisai

12

Papers

97

Citations

Citation Trend

Filter By

Papers (9) Sort By

Journal Conference Others

First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor.

2020 British Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (16)
Abstract 3269: Discovery and characterization of E7766, a novel macrocycle-bridged STING agonist with pan-genotypic and potent antitumor activity through intravesical and intratumoral administration

2019 Immunology
Show All
- Source
- Cite
- Save
Citations (3)
Safety, pharmacokinetics, and pharmacodynamics in first-in-human study of a novel compound E6742, a Toll-like receptor 7 and 8 antagonist

2018
Show All
- Source
- Cite
- Save
Citations (2)
Abstract 5050: Pharmacodynamic and pharmacokinetic relationship of single agent E7449 in patients with advanced solid tumors or B-cell malignancies

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract P5-06-03: Combination of the PARP inhibitor E7449 with eribulin +/- carboplatin in preclinical models of triple negative breast cancer

2015 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
Pharmacodynamic biomarkers of outcomes in the phase III study of lenvatinib in 131I-refractory differentiated thyroid cancer (SELECT).

2015 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (6)
Phase 1 study of the PARP inhibitor E7449 as a single agent in patients with advanced solid tumors or B-cell lymphoma.

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Clinical study of E2609, a novel BACE1 inhibitor, demonstrates target engagement and inhibition of BACE1 activity in CSF

2013 Alzheimers & Dementia
Show All
- Source
- Cite
- Save
Citations (18)
Abstract 3323: E7449, a potent inhibitor of PARP 1 and 2, is active in acute myeloid leukemia.

2013 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)